The TRIM proteins in cancer: from expression to emerging regulatory mechanisms.

Autor: Mohammadi A; Department of Genetics Islamic, Azad University of Marand, Marand, Iran., Pour Abbasi MS; Kashan University of Medical Sciences, Kashan, Iran., Khorrami S; Tehran University of Medical Sciences, Tehran, Iran., Khodamoradi S; Department of Microbiology, Shahr-e-Qods Branch, Islamic Azad University, Tehran, Iran., Mohammadi Goldar Z; Department of Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran., Ebrahimzadeh F; Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. ebrahimzadehf@mums.ac.ir.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2022 Mar; Vol. 24 (3), pp. 460-470. Date of Electronic Publication: 2021 Oct 13.
DOI: 10.1007/s12094-021-02715-5
Abstrakt: New clinical evidence suggests that dysregulation of the ubiquitin-mediated destruction of tumor suppressors or oncogene products is probably engaged in the etiology of leukemia and carcinoma. The superfamily of tripartite motif (TRIM)-containing protein family is among the biggest recognized single protein RING finger E3 ubiquitin ligases that are considered vital carcinogenesis regulators, which is not shocking since TRIM proteins are engaged in various biological processes, including cell growth, development, and differentiation; hence, TRIM proteins' alterations may influence apoptosis, cell proliferation, and transcriptional regulation. In this review article, the various mechanisms through which TRIM proteins exert their role in the most prevalent malignancies including lung, prostate, colorectal, liver, breast, brain cancer, and leukemia are summarized.
(© 2021. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).)
Databáze: MEDLINE
Externí odkaz: